0001415889-24-015590.txt : 20240605 0001415889-24-015590.hdr.sgml : 20240605 20240605165941 ACCESSION NUMBER: 0001415889-24-015590 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gilbert Halley E CENTRAL INDEX KEY: 0001601360 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 241022790 MAIL ADDRESS: STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC. STREET 2: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 form4-06052024_080637.xml X0508 4 2024-06-03 0001649094 Vaxcyte, Inc. PCVX 0001601360 Gilbert Halley E C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 true false false false 1 Common Stock 2024-06-03 4 M 0 18200 5.35 A 23825 D Common Stock 2024-06-03 4 S 0 18200 73 D 5625 D Stock Option (Right to Buy) 5.35 2024-06-03 4 M 0 18200 0 D 2030-04-17 Common Stock 18200 30374 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. Option is fully vested and exercisable. Reporting Person has transferred 30,374 vested stock options to Reporting Person's ex-spouse pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Accordingly, Reporting Person will not report beneficial ownership of or dispositions or acquisitions of the underlying shares in future Section 16(a) filings. /s/ Ron A. Metzger, Attorney-in-Fact 2024-06-05